Posted by Michael Wonder on 24 Nov 2015
European Commission approves Amgen's Blincyto (blinatumomab) for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B precursor acute lymphoblastic leukaemia
23 November 2015 - Blincyto is the first bispecific T Cell engager (BiTE) antibody construct approved in the European Union.
